-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NFy5tMxWIbm8oWFSU/9bPRfZOjc7hM3MfEJmH/2gYSOqHea+gXK7HjEpeZN8Lk9C
 MkNmKTLyxRAYjqq20nxyHw==

<SEC-DOCUMENT>0001005477-03-004016.txt : 20031002
<SEC-HEADER>0001005477-03-004016.hdr.sgml : 20031002
<ACCEPTANCE-DATETIME>20031002211624
ACCESSION NUMBER:		0001005477-03-004016
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20030930
FILED AS OF DATE:		20031002

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			LEBUHN ROBERT
		CENTRAL INDEX KEY:			0001007931

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-12957
		FILM NUMBER:		03926153

	BUSINESS ADDRESS:	
		STREET 1:		222 S 15TH STREET
		STREET 2:		SUITE 600 N
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68102

	MAIL ADDRESS:	
		STREET 1:		222 S 15TH STREET
		STREET 2:		SUITE 600 N
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68102

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ENZON PHARMACEUTICALS  INC
		CENTRAL INDEX KEY:			0000727510
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				222372868
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	BUSINESS ADDRESS:	
		STREET 1:		685 ROUTE 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		7329804500

	MAIL ADDRESS:	
		STREET 1:		C/O DORSEY & WHITNEY LLP
		STREET 2:		250 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10177

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ENZON PHARMACEUTICAL  INC
		DATE OF NAME CHANGE:	20021210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ENZON INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>edgar123.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0201</schemaVersion>

    <documentType>4</documentType>
    <periodOfReport>2003-09-30</periodOfReport>
    <notSubjectToSection16>0</notSubjectToSection16>
    <issuer>
        <issuerCik>0000727510</issuerCik>
        <issuerName>ENZON PHARMACEUTICALS  INC</issuerName>
        <issuerTradingSymbol>enzn</issuerTradingSymbol>
    </issuer>

    <reportingOwner>

        <reportingOwnerId>
            <rptOwnerCik>0001007931</rptOwnerCik>
            <rptOwnerName>LEBUHN ROBERT</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ENZON PHARMACEUTICALS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>685 ROUTE 202/206</rptOwnerStreet2>
            <rptOwnerCity>BRIDGEWATER</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>08807</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
            <reportingOwnerRelationship>
        <isDirector>1</isDirector>
        <isOfficer>0</isOfficer>
        <isTenPercentOwner>0</isTenPercentOwner>
        <isOther>0</isOther>
    </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>

        <securityTitle>
            <value>Common Stock Right</value>
            <footnoteId id="F1"/>
        </securityTitle>

        <conversionOrExercisePrice>
            <value>0</value>
            <footnoteId id="F2"/>
        </conversionOrExercisePrice>

        <transactionDate>
            <value>2003-09-30</value>
        </transactionDate>
    <transactionCoding>
        <transactionFormType>4</transactionFormType>
        <transactionCode>A</transactionCode>
        <equitySwapInvolved>0</equitySwapInvolved>
    </transactionCoding>
        <transactionAmounts>

            <transactionShares>
                <value>344</value>
            </transactionShares>

            <transactionPricePerShare>
                <value>0</value>
            </transactionPricePerShare>

            <transactionAcquiredDisposedCode>
                <value>A</value>
            </transactionAcquiredDisposedCode>
        </transactionAmounts>

        <exerciseDate>
            <value>2004-01-01</value>
            <footnoteId id="F1"/>
        </exerciseDate>

        <expirationDate>
            <value>2004-06-30</value>
            <footnoteId id="F1"/>
        </expirationDate>
        <underlyingSecurity>

            <underlyingSecurityTitle>
                <value>Common Stock</value>
            </underlyingSecurityTitle>

            <underlyingSecurityShares>
                <value>344</value>
            </underlyingSecurityShares>
        </underlyingSecurity>
        <postTransactionAmounts>

            <sharesOwnedFollowingTransaction>
                <value>344</value>
            </sharesOwnedFollowingTransaction>
        </postTransactionAmounts>
        <ownershipNature>

            <directOrIndirectOwnership>
                <value>D</value>
            </directOrIndirectOwnership>
        </ownershipNature>
        </derivativeTransaction>

    </derivativeTable>
    <footnotes>
        <footnote id="F1">Securities granted by Enzon Pharmaceuticals, Inc. persuant to Enzon's 2001 Incentive Stock Plan as compensation for service as an Independent Director during the quarter ended September 30, 2003 and qualified under Rule 16b-3(d).  The value of the compensation was $4,000.  In the spring of 2004, each Common Stock right will be exchanged for one share of Common Stock; provided, however, Mr. LeBuhn will be entitled to elect to receive cash for up to 50% of these rights, with the price per right being $11.64, the fair market value of Enzon's common stock on September 30, 2003.</footnote>
        <footnote id="F2">On a 1-for-1 basis.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Kenneth J. Zuerblis (Attorney in Fact)</signatureName>
        <signatureDate>2003-10-02</signatureDate>
    </ownerSignature>

</ownershipDocument>

</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----